Sorrento Stock Is a Buy Because of Its Strong Drug Pipeline, Says Analyst

TipRanks2021-03-05

Sorrento (SRNE) has a multi-pronged approach to therapeutics. The company has been constantly adding new options to its bulging pipeline and has made two notable additions over the past month. Earlier...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2117501807?lang=zh_CN&edition=full","thumbnail":"https://s.yimg.com/uu/api/res/1.2/SIkHKEAXkZblkY98rUX3sw--~B/aD00NTE7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/siJU_0HHf5KcEvF65dh0_A--~B/aD00NTE7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/8f3522e85fa7214f56e653c55216edfa","is_english":true,"pubTime":"2021-03-05 01:15","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2117501807","market":"us","top_or_hot":-1,"title":"Sorrento Stock Is a Buy Because of Its Strong Drug Pipeline, Says Analyst","media":"TipRanks","content":"<div>\n<p>Sorrento (SRNE) has a multi-pronged approach to therapeutics. The company has been constantly adding new options to its bulging pipeline and has made two notable additions over the past month.\nEarlier...</p>\n\n<a href=\"https://finance.yahoo.com/news/protected-sorrento-stock-buy-because-171544278.html\">网页链接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sorrento Stock Is a Buy Because of Its Strong Drug Pipeline, Says Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSorrento Stock Is a Buy Because of Its Strong Drug Pipeline, Says Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-05 01:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/protected-sorrento-stock-buy-because-171544278.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sorrento (SRNE) has a multi-pronged approach to therapeutics. The company has been constantly adding new options to its bulging pipeline and has made two notable additions over the past month.\nEarlier...</p>\n\n<a href=\"https://finance.yahoo.com/news/protected-sorrento-stock-buy-because-171544278.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SRNE","symbol_name":"索伦托医疗","start_time":0,"source_url":"https://finance.yahoo.com/news/protected-sorrento-stock-buy-because-171544278.html","article_id":"2117501807","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/SIkHKEAXkZblkY98rUX3sw--~B/aD00NTE7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/siJU_0HHf5KcEvF65dh0_A--~B/aD00NTE7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/8f3522e85fa7214f56e653c55216edfa"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/protected-sorrento-stock-buy-because-171544278.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2117501807","pubTimestamp":1614878144,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Sorrento (SRNE) has a multi-pronged approach to therapeutics. The company has been constantly adding","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SRNE":"索伦托医疗"},"translate_title":"分析师说，索伦托的股票是买入的，因为它有强大的药品供应渠道","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRNE":0.9},"content_text":"Sorrento (SRNE) has a multi-pronged approach to therapeutics. The company has been constantly adding new options to its bulging pipeline and has made two notable additions over the past month.\nEarlier this week, Sorrento and majority-owned subsidiary Scilex disclosed they are signing an exclusive licensing deal with Aardvark Therapeutics, which will bring ARD-301 under the ever-expanding Sorrento umbrella.\nARD-301, Aardvark’s proprietary LDN (Low Dose Naltrexone) formulation is intended to treat chronic pain, fibromyalgia, and chronic post-COVID syndrome (“long COVID”) and will augment the company’s non-opioid pain franchise.\nScilex plans to kick off a new Phase 2 trial this year for both fibromyalgia and chronic post-COVID syndrome.\nIn previous clinical studies with LDN, the non-opioid, non-addictive therapeutic has displayed activity that has improved a wide array of fibromyalgia symptoms. Right now, for the disorder, there are just 3 FDA approved treatments.\n“With ARD-301, Scilex is adding a key tool to physicians’ therapeutic armamentarium for treating fibromyalgia, a chronic disorder characterized by musculoskeletal pain that affects ~10M U.S. adults,” said B. Riley analyst Mayank Mamtani. \"ARD-301 also serves as a bridge to SRNE's two of three core therapeutic areas (TAs) in non-opioid pain and C-19.”\nThe latest move follows last month’s announcement of another addition; Sorrento is purchasing the outstanding equity of ANP Technologies for a total of $100 million.\nThe acquisition will not only give Sorrento access to a “diverse pipeline” based on ANP’s Nano Intelligent Detection/Delivery System (NIDS®) for the identification of chemical and bio-warfare agents, but adds a second EUA-stage Covid-19 diagnostic to its arsenal.\nMamtani says the acquisition will bring in “extra capacity to produce COVID test kits and provide the know-how to optimize the assay through improving detection capabilities, thereby conferring increased sensitivity and specificity.”\nAll in all, Mamtani keeps a Buy rating on SRNE shares, alongside a $26 price target. The implication for investors? Upside of a hefty 192%. (To watch Mamtani’s track record, click here)\nBig gains are also anticipated by Mamtani’s colleagues. The even higher $28 average price target implies the stock will be changing hands for a 209% premium a year for now. All 4 analysts keeping a tab on Sorrento rate it a Buy, resulting in a Strong Buy consensus rating. (See SRNE stock analysis on TipRanks)\n\n\n\n\n\nTo find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.\nDisclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2117501807"}